ArticleGenes & genomics2026
Integrative analysis of TCGA data identifies hsa-miR-200a as a breast cancer-associated microRNA biomarker with exploratory serum validation.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundBreast cancer is a biologically heterogeneous disease, and reliable non-invasive biomarkers are needed to improve early detection and clinical risk stratification. MicroRNAs (miRNAs) represent promising diagnostic candidates due to their regulatory roles in tumor-associated gene expression.
objectiveIn this study, an integrative analysis of miRNA and mRNA expression profiles was performed using paired tumor and normal samples from the TCGA-BRCA cohort to identify diagnostically relevant miRNAs.
methodsDifferential expression analysis and receiver operating characteristic (ROC) curve analysis were used to identify miRNAs with high discriminatory capacity. Priority was given to candidates showing strong inverse correlation with predicted target genes. A logistic regression model was developed for internal validation using a held-out test set, and exploratory clinical serum analysis was conducted using qRT-PCR on serum samples from breast cancer patients and healthy controls.
resultsMultiple upregulated miRNAs with strong discriminatory capacity (AUC values > 0.90) were identified. Among these, hsa-miR-200a was prioritized based on consistently high diagnostic accuracy and a strong inverse correlation with its predicted target gene, TNS1. hsa-miR-200a expression was elevated across pathological stages and molecular subtypes, whereas TNS1 expression was progressively reduced. The logistic regression model achieved an accuracy of 92.9% and a sensitivity of 96.7% in a held-out internal test set. Exploratory serum analysis suggested altered circulating hsa-miR-200a-5p patterns, with distinct perioperative dynamics according to clinical risk.
conclusionsThese findings support hsa-miR-200a as a potential breast cancer-associated miRNA biomarker candidate and highlight the utility of integrative transcriptomic and exploratory clinical serum approaches for future precision diagnostics.
Indexed as
Identifiers
42560646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.